文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

二尖瓣经导管缘对缘修复前心力衰竭药物治疗现状:STS/ACC TVT注册研究

Heart failure medical therapy prior to mitral transcatheter edge-to-edge repair: the STS/ACC Transcatheter Valve Therapy Registry.
PubMed 文献 · Eur Heart J · 2023-01-01

该研究基于STS/ACC TVT注册,纳入4199例LVEF<50%因功能性二尖瓣反流接受MTEER的患者,评估术前指南导向药物治疗(GDMT)使用情况。仅19.2%接受三联治疗,6.5%未用GDMT,中心间差异显著。在可随访的2014例中,三联和双联治疗与1年死亡或心衰住院风险降低独立相关。

要点

  • MTEER术前仅19.2%患者接受三联GDMT,6.5%未用任何GDMT。
  • 中心间三联治疗比例差异大(0%-61%),调整中位OR 1.48。
  • 三联和双联治疗与1年死亡或心衰住院风险降低独立相关。

核心结论

  • 在美国 nationwide 注册中,LVEF<50%因FMR接受MTEER的患者术前综合GDMT使用不足,仅不到五分之一接受三联治疗,且中心间差异显著。
  • 与无/单药治疗相比,MTEER术前三联和双联治疗与1年死亡或心衰住院风险降低独立相关。

研究设计与样本

  • 研究为基于STS/ACC Transcatheter Valve Therapy Registry的回顾性队列分析。
  • 纳入2019年7月23日至2022年3月31日因FMR接受MTEER且LVEF<50%的患者,共4199例,来自449个中心。
  • 采用Cox比例风险模型评估术前GDMT(无/单药、双联或三联)与1年死亡或心衰住院风险的关联。

主要发现

  • 术前使用β受体阻滞剂、ACEI/ARB、MRA和ARNI的比例分别为85.1%、44.4%、28.6%和19.9%。
  • 三联治疗占19.2%,双联治疗占38.2%,单药治疗占36.0%,未用GDMT占6.5%。

临床怎么用

  • 对于LVEF<50%的重度功能性二尖瓣反流患者,在考虑MTEER前应评估并优化GDMT,尤其应关注三联治疗的使用。
  • 临床实践中需注意中心间GDMT使用差异,可考虑通过流程优化提高术前GDMT依从性。

局限性

  • 研究为注册登记回顾性分析,可能存在未测量混杂因素。
  • 1年随访分析仅纳入部分患者(n=2014),可能存在选择偏倚。
  • 原文未报告药物剂量、禁忌证及治疗调整原因等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Guideline-directed medical therapy (GDMT) is recommended before mitral valve transcatheter edge-to-edge repair (MTEER) in patients with heart failure (HF) and severe functional mitral regurgitation (FMR). Whether MTEER is being performed on the background of optimal GDMT in clinical practice is unknown. METHODS: Patients with left ventricular ejection fraction (LVEF) < 50% who underwent MTEER for FMR from 23 July 2019 to 31 March 2022 in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry were identified. Pre-procedure GDMT utilization was assessed. Cox proportional hazards models were constructed to evaluate associations between pre-MTEER therapy (no/single, double, or triple therapy) and risk of 1-year mortality or HF hospitalization (HFH). RESULTS: Among 4199 patients across 449 sites, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, mineralocorticoid receptor antagonists, and angiotensin receptor-neprilysin inhibitors were used in 85.1%, 44.4%, 28.6%, and 19.9% before MTEER, respectively. Triple therapy was prescribed for 19.2%, double therapy for 38.2%, single therapy for 36.0%, and 6.5% were on no GDMT. Significant centre-level variation in the proportion of patients on pre-intervention triple therapy was observed (0%-61%; adjusted median odds ratio 1.48 [95% confidence interval (CI) 1.25-3.88]; P < .001). In patients eligible for 1-year follow-up (n = 2014; 341 sites), the composite rate of 1-year mortality or HFH was lowest in patients prescribed triple therapy (23.0%) compared with double (24.8%), single (35.7%), and no (41.1%) therapy (P < .01 comparing across groups). Associations persisted after accounting for relevant clinical characteristics, with lower risk in patients prescribed triple therapy [adjusted hazard ratio (aHR) 0.73, 95% CI .55-.97] and double therapy (aHR 0.69, 95% CI .56-.86) before MTEER compared with no/single therapy. CONCLUSIONS: Under one-fifth of patients with LVEF <50% who underwent MTEER for FMR in this US nationwide registry were prescribed comprehensive GDMT, with substantial variation across sites. Compared with no/single therapy, triple and double therapy before MTEER were independently associated with reduced risk of mortality or HFH 1 year after intervention.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Varshney AS, Shah M, Vemulapalli S, et al. Heart failure medical therapy prior to mitral transcatheter edge-to-edge repair: the STS/ACC Transcatheter Valve Therapy Registry. Eur Heart J. 2023. PMID: 37632738. doi:10.1093/eurheartj/ehad584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。